OVID — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-13

• Other income (expense), net, for the three months ended June 30, 2026 and 2025 were gains of $0.7 million and $0.4 million, respectively. Items reflected in other income (expense), net, in both periods were primarily interest income and accretion on U.S. treasury investments, as well as unrealized l…

• The following table summarizes the results of our operations for the periods indicated:

• Six Months Ended June 30, 2026Six Months Ended June 30, 2025Change $

• Revenue of $0.7 million was generated in the six months ended June 30, 2026, compared to revenue of $6.4 million recognized for the same period in 2025, which related to our royalty and licensing agreements with NewCo, Marinus and Immedica (see Note 10 to our condensed consolidated financial stateme…

• Six Months Ended June 30, 2026Six Months Ended June 30, 2025Change $

Text removed vs the prior filing · source: 10-Q · 2026-05-12

• In October 2025, we entered into a Securities Purchase Agreement with the purchasers named therein (the “2025 Investors”), which included Series A warrants (the “Series A Warrants”) to purchase up to 38,481,325 shares of our common stock, par value $0.001 per share, and/or pre-funded warrants to pur…

• On March 18, 2026, we publicly announced that we received approval from Human Research Ethics Committee and acknowledgment of our Clinical Trial Notification from the Australian Therapeutic Goods Administration to initiate the Phase 1 clinical trial of KCC2 direct activator compound, OV4071, in Aust…

• On March 17, 2026, we entered into a Securities Purchase Agreement with the purchasers named therein (the “2026 Investors”), pursuant to which we agreed to issue and sell an aggregate of 19,154,321 shares of our common stock at a purchase price of $2.01 per share and, in lieu of common stock, Pre-Fu…

• placement (the “2026 Private Placement”). The Pre-Funded Warrants have an exercise price of $0.001 per share and are immediately exercisable. We received net proceeds from the 2026 Private Placement of $56.2 million, after deducting placement agent fees and offering expenses. We intend to use the ne…

• specific tasks using data such as patient enrollment, clinical site activations or other information provided to us by our vendors.

Text added vs the prior filing · source: 10-Q · 2026-08-13

• respective business associates, individuals or entities that perform certain services on behalf of a covered entity that involves the use or disclosure of individually identifiable health information and their subcontractors that use, disclose or otherwise process individually identifiable health in…

• At the state level, legislatures have increasingly passed and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transpare…

• reductions in force at various government agencies including the FDA, and has implemented layoffs at the FDA, which could significantly reduce the FDA’s capacity to perform its functions in a manner consistent with its past practices and could delay reviews and negatively impact our business.

• In addition, our employees use generative AI technologies in certain circumstances to perform portions of their work. There can be no assurance that employees will not inadvertently or improperly input information that is proprietary, confidential, or sensitive, including trade secrets, into AI syst…

• limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case.

Text removed vs the prior filing · source: 10-Q · 2026-05-12

• information and their subcontractors that use, disclose or otherwise process individually identifiable health information;

• At the state level, legislatures have increasingly passed and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transpare…

• drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing.

• patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future drug candidates.

• Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects.